Literature DB >> 1973621

Corticotropin-releasing hormone, luteinizing hormone-releasing hormone, growth hormone-releasing hormone, and somatostatin-like immunoreactivities in biopsies from breast cancer patients.

D R Ciocca1, L A Puy, L C Fasoli, O Tello, J C Aznar, F E Gago, S I Papa, R Sonego.   

Abstract

The presence of immunoreactive adrenocorticotropin-releasing hormone (CRH), luteinizing hormone-releasing hormone (LHRH), growth hormone-releasing hormone (GHRH), and somatostatin has been investigated by immunohistochemistry in forty biopsies from breast cancer patients. All of these hypothalamic hormones were found in about 30% of the samples, seen in the cytoplasm or in the nuclei of the tumor cells. Positive immunostaining for the hypothalamic hormones was present in colloid, lobular, and infiltrating ductal carcinomas. There was not a clear relationship between occurrence of staining for the hypothalamic hormones and the histologic grade of tumors or the clinical stage of the disease. Immunoreactive LHRH was more frequently found in breast tumors with estrogen and progesterone receptors. On the other hand, preneoplastic breast lesions expressed mainly somatostatin, while immunoreactivity was absent in normal mammary tissue.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1973621     DOI: 10.1007/bf01806354

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  37 in total

Review 1.  Physiological and clinical studies of GRF and GH.

Authors:  M O Thorner; M L Vance; W S Evans; R M Blizzard; A D Rogol; K Ho; D A Leong; J L Borges; M J Cronin; R M MacLeod
Journal:  Recent Prog Horm Res       Date:  1986

2.  Prognostic usefulness of estrogen receptor immunocytochemical assays for human breast cancer.

Authors:  E R DeSombre; S M Thorpe; C Rose; R R Blough; K W Andersen; B B Rasmussen; W J King
Journal:  Cancer Res       Date:  1986-08       Impact factor: 12.701

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Immunoreactive corticotropin and corticotropin-releasing factor in human hypothalamus, adrenal, lung cancer, and pheochromocytoma.

Authors:  T Suda; N Tomori; F Tozawa; H Demura; K Shizume; T Mouri; Y Miura; N Sasano
Journal:  J Clin Endocrinol Metab       Date:  1984-05       Impact factor: 5.958

5.  Immunochemical demonstration of immunoreactive insulin in human breast cancer.

Authors:  A Castro; J Ziegels-Weissman; P Buschbaum; W Voigt; A Morales; M Nadji
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1980-07

6.  Gonadotropin-releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists.

Authors:  K A Eidne; C A Flanagan; N S Harris; R P Millar
Journal:  J Clin Endocrinol Metab       Date:  1987-03       Impact factor: 5.958

7.  Corticotropin-releasing factor (CRF)-like immunoreactivity in the gastro-entero-pancreatic endocrine system.

Authors:  P Petrusz; I Merchenthaler; P Ordronneau; J L Maderdrut; S Vigh; A V Schally
Journal:  Peptides       Date:  1984       Impact factor: 3.750

8.  Ectopic production of lipotropin by cancer.

Authors:  W D Odell; A R Wolfsen; I Bachelot; F M Hirose
Journal:  Am J Med       Date:  1979-04       Impact factor: 4.965

Review 9.  Growth hormone-releasing hormone-producing tumors: clinical, biochemical, and morphological manifestations.

Authors:  T Sano; S L Asa; K Kovacs
Journal:  Endocr Rev       Date:  1988-08       Impact factor: 19.871

10.  Corticotropin-releasing factor (CRF)-like immunoreactivity in the vertebrate endocrine pancreas.

Authors:  P Petrusz; I Merchenthaler; J L Maderdrut; S Vigh; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1983-03       Impact factor: 11.205

View more
  15 in total

Review 1.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

Review 2.  The corticotropin releasing factor system in cancer: expression and pathophysiological implications.

Authors:  Athina Kaprara; Kalliopi Pazaitou-Panayiotou; Alexandros Kortsaris; Ekaterini Chatzaki
Journal:  Cell Mol Life Sci       Date:  2010-02-09       Impact factor: 9.261

Review 3.  Systemic therapy in breast cancer: efficacy and cost utility.

Authors:  J F Corry; P E Lønning
Journal:  Pharmacoeconomics       Date:  1994-03       Impact factor: 4.981

4.  Synthesis, F-18 radiolabeling, and microPET evaluation of 3-(2,4-dichlorophenyl)-N-alkyl-N-fluoroalkyl-2,5-dimethylpyrazolo[1,5-a]pyrimidin-7-amines as ligands of the corticotropin-releasing factor type-1 (CRF1) receptor.

Authors:  Jeffrey S Stehouwer; Matthew S Birnbaum; Ronald J Voll; Michael J Owens; Susan J Plott; Chase H Bourke; Michael A Wassef; Clinton D Kilts; Mark M Goodman
Journal:  Bioorg Med Chem       Date:  2015-06-19       Impact factor: 3.641

Review 5.  Ectopic secretion of growth hormone-releasing hormone in man.

Authors:  M Losa; J Schopohl; K von Werder
Journal:  J Endocrinol Invest       Date:  1993-01       Impact factor: 4.256

6.  Corticotropin-releasing factor reduces tumor volume, halts further growth, and enhances the effect of chemotherapy in 4T1 mammary carcinoma in mice.

Authors:  Linda E B Stuhr; Eddie T Wei; Rolf K Reed
Journal:  Tumour Biol       Date:  2013-09-18

7.  Corticotropin-releasing hormone (CRH) is expressed in the human cervical carcinoma cells (HeLa) and upregulates the expression of Fas ligand.

Authors:  Eirini Taliouri; Thomas Vrekoussis; Aikaterini Vergetaki; Theodore Agorastos; Antonis Makrigiannakis
Journal:  Tumour Biol       Date:  2012-10-18

8.  Characterization of binding sites for a GnRH-agonist (buserelin) in human breast cancer biopsies and their distribution in relation to tumor parameters.

Authors:  K H Baumann; L Kiesel; M Kaufmann; G Bastert; B Runnebaum
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

9.  Stress-Derived Corticotropin Releasing Factor Breaches Epithelial Endotoxin Tolerance.

Authors:  Yong Yu; Zhi-Qiang Liu; Xiao-Yu Liu; Li Yang; Xiao-Rui Geng; Gui Yang; Zhi-Gang Liu; Peng-Yuan Zheng; Ping-Chang Yang
Journal:  PLoS One       Date:  2013-06-19       Impact factor: 3.240

10.  Colocalization of somatostatin receptors and epidermal growth factor receptors in breast cancer cells.

Authors:  Heather L Watt; Ujendra Kumar
Journal:  Cancer Cell Int       Date:  2006-03-06       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.